Back to search results

Aerobic Training for People Receiving Treatment for Breast Cancer

This study is looking at how different types of walking programs, called Aerobic Training (AT), affect women receiving treatment for breast cancer. Researchers are comparing two approaches: "Standard AT," which involves a fixed amount of walking each week, and "Adaptive AT," where the amount of walking adjusts based on how your body responds. The goal is to see how both programs impact your cardiorespiratory fitness (CRF), which is how well your heart and lungs work. You might be able to join if you are an adult woman (18 or older) with breast cancer who is scheduled for systemic (body-wide) or local treatment, and you currently exercise for 90 minutes or less per week. The study aims to enroll 140 participants.

Study design
This is an interventional study comparing two different walking programs. It plans to enroll 140 participants.
What's involved
You would participate in supervised walking sessions up to 7 days per week for about 32 weeks, followed by a potential 20-week phase. Your cardiorespiratory fitness will be measured at 32 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your cardiorespiratory fitness will be measured at 32 weeks from the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05716893

Study of Aerobic Training for People Receiving Treatment for Breast Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~140 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Adaptive Aerobic Training/AT DosingStandard (fixed) Aerobic Training/AT dosing

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cardiorespiratory fitness (CRF) response rate
Measured over 32 weeks from baseline

Conditions

Breast Cancer
Breast Carcinoma

Explore related trials

Breast Carcinoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Jessica Scott, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Jessica Scott, PhD
[email protected]
646-888-8093
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged ≥18 years
Female
Diagnosed with primary breast cancer as defined by one of the following:
Histological confirmation
As per standard of care imaging
Scheduled to receive neoadjuvant/adjuvant systemic and/or locoregional therapy
Performing ≤90 minutes of moderate- and/or strenuous-intensity exercise per week, as evaluated by self-report
Willingness to comply with all study-related procedures
Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:

Exclusion

Enrollment onto any other interventional investigational study, except interventions determined by the PI not to confound study outcomes
Receiving treatment for any other diagnosis of invasive cancer
Distant metastatic malignancy of any kind
Mental impairment leading to inability to cooperate
Any of the following contraindications to cardiopulmonary exercise testing:
Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

What this trial measures

  • Cardiorespiratory fitness (CRF) response rate32 weeks from baseline

    The primary endpoint will be CRF response rate as assessed by the proportion of patients with a peak oxygen consumption (VO2peak; ml O2 .kg-1.min-1 ) change from baseline (T0) to T2 (\~32 weeks) of ≥3.50 ml O2 .kg-1.min-1 . A CRF change ≥3.50 ml O2 .kg-1.min-1 will be considered a response; a change \<3.50 ml O2 .kg-1.min-1 will be considered a non-response.